Sino Biopharmaceutical Full Year 2023 Earnings: Misses Expectations

Sino Biopharmaceutical (HKG:1177) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥26.2b (flat on FY 2022).
• Net income: CN¥1.85b (down 10% from FY 2022).
• Profit margin: 7.1% (down from 7.9% in FY 2022).
• EPS: CN¥0.10 (down from CN¥0.11 in FY 2022).

1177 Post-Clinical Trial Products

• Approved (during full year): 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sino Biopharmaceutical Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 17%.

Looking ahead, revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Pharmaceuticals industry in Hong Kong.

Performance of the Hong Kong Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of Sino Biopharmaceutical's balance sheet and an in-depth analysis of the company's financial position.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.